AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38452779
Drug: 7-day primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day primaquine 0.5 mg/kg per day
Trial: 38452779
Drug: Weekly primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly primaquine 0.75 mg/kg for 8 weeks
Trial: 38452788
Drug: ASTX727 (cedazuridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTX727 (cedazuridine 100 mg and decitabine 35 mg) plus venetoclax 400 mg
Trial: 38453435
Drug: VS-505 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS-505 2.25 g/day
Trial: 38453435
Drug: VS-505 1.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS-505 1.50 g/day
Trial: 38453435
Drug: VS-505 4.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS-505 4.50 g/day
Trial: 38453435
Drug: Sevelamer carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer carbonate 4.80 g/day
Trial: 38453781
Drug: TOP2A+ group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOP2A+ group received FEC100 for 3 cycles followed by 3 cycles of Trastuzumab (8 mg/kg then 6 mg/kg), Pertuzumab (840 mg/kg then 420 mg/kg), and Docetaxel (75 mg/m2).
Trial: 38453781
Drug: TOP2A- group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOP2A- group received the same chemotherapy regimen as TOP2A+ group.
Trial: 38453781
Drug: TOP2A+ group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOP2A+ group received the same chemotherapy regimen as TOP2A- group.
Trial: 38455033
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control arm receiving treatment information by mobile phone in addition to standard care.
Trial: 38455366
Drug: Hemay022 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemay022 at doses of 50-600 mg QD and 300 mg BID
Trial: 38455850
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 500 mg tablets, three times per day (total dose of 1500 mg/day) for eight weeks
Trial: 38455935
Drug: Biological, genetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological, genetic and microbiological analyses
Trial: 38456042
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment linkage strategies
Trial: 38456291
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (2 × 12 mg)
Trial: 38456660
Drug: Navitoclax (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax (250 mg daily days 1 to 28) and Trametinib (2 mg daily days 1 to 14)
Trial: 38456703
Drug: Triple-dose CoronaVac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-dose CoronaVac
Trial: 38456874
Drug: Discharge GDMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge GDMT prescription after CABG surgery
Trial: 38456874
Drug: Discharge GDMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge GDMT prescription
Trial: 38457177
Drug: Folic acid-fortified
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid-fortified iodized salt (300 µg/d of folic acid)
Trial: 38457361
Drug: ML-ratio (monocytes-to-lymphocytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML-ratio (monocytes-to-lymphocytes ratio) (tenth decile > 2.02)
Trial: 38458016
Drug: Biofeedback intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biofeedback intervention consisting of weekly one-hour sessions combining heart rate variability and temperature biofeedback for six weeks.
Trial: 38458039
Drug: Durvalumab (immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (immune checkpoint inhibitor) in Group A (PIK3CA alterations)
Trial: 38458039
Drug: Durvalumab (immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (immune checkpoint inhibitor) in Group B (cell cycle pathway alterations)
Trial: 38458039
Drug: Durvalumab (immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (immune checkpoint inhibitor) in Group C (no druggable genetic alterations)
Trial: 38458039
Drug: Durvalumab (immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (immune checkpoint inhibitor) in Group A
Trial: 38458039
Drug: Durvalumab (immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (immune checkpoint inhibitor) in Group B
Trial: 38458039
Drug: Durvalumab (immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (immune checkpoint inhibitor) in Group C
Trial: 38458208
Drug: Paracetamol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol plus dexamethasone
Trial: 38458208
Drug: Ibuprofen plus
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen plus dexamethasone
Trial: 38458208
Drug: Paracetamol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol plus ibuprofen plus dexamethasone
Trial: 38458408
Drug: Double etonogestrel
RxNorm normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double etonogestrel implant (136 mg)
Trial: 38458408
Drug: Single etonogestrel
RxNorm normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single etonogestrel implant (68 mg)
Trial: 38458577
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g cooked iron-fortified lentils (IFLs)
Trial: 38458577
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g cooked noniron-fortified lentils (NIFLs)
Trial: 38458635
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy (nCRT) combined with PD-1 inhibitor toripalimab
Trial: 38458788
Drug: KOOS Activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KOOS Activities of daily living score
Trial: 38458796
Drug: Other antihypertensive
RxNorm normalized name: Other antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihypertensive medicines (AHT)
Trial: 38458816
Drug: PRaG regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRaG regimen (thymalfasin, PD-1/PD-L1 inhibitor, GM-CSF)
Trial: 38458816
Drug: PRaG regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRaG regimen (thymalfasin, PD-1/PD-L1 inhibitor)
Trial: 38459072
Drug: S. sonnei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. sonnei Generalized Modules for Membrane Antigen (GMMA)-based vaccine (1790GAHB)
Trial: 38459338
Drug: INS018_055 (small-molecule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS018_055 (small-molecule TNIK inhibitor)
Trial: 38459584
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy and imaging including both CT and MRI
Trial: 38459869
Drug: Tegoprazan (TPZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan (TPZ), amoxicillin, clarithromycin, and bismuth (300 mg twice daily)
Trial: 38459869
Drug: Tegoprazan (TPZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan (TPZ), amoxicillin, and clarithromycin (without bismuth)
Trial: 38460082
Drug: Ensitrelvir 375
RxNorm normalized name: ensitrelvir
DrugBank: Ensitrelvir (DB18834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensitrelvir 375 mg single dose
Trial: 38460092
Drug: Gender-affirming hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gender-affirming hormone treatment (GAHT) in transgender women (TW) after sex hormone inhibition and estradiol treatment.
Trial: 38460092
Drug: Gender-affirming hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gender-affirming hormone treatment (GAHT) in transgender men (TM) after estrogen suppression and testosterone treatment.
Trial: 38460525
Drug: Bivalent vaccine
RxNorm normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent vaccine (NVX-CoV2373 + NVX-CoV2540)
Trial: 38460525
Drug: Prototype vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype vaccine (NVX-CoV2373)
Trial: 38460974
Drug: Mechanical insufflation-exsufflation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical insufflation-exsufflation (MI-E) delivered by an experienced physiotherapist, with four cycles at a range of prescriptions.
Trial: 38461094
Drug: 150-mg daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-mg daily aspirin
Trial: 38461275
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy for Suicide Prevention (CTSP) + Services as Usual (SAU) (N=150)
Trial: 38461313
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml natural aronia juice (verum, V) twice daily
Trial: 38461731
Drug: Domperidone add-on
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone add-on 10-mg three times daily for 16 weeks
Trial: 38461731
Drug: No add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No add-on treatment (control)
Trial: 38461843
Drug: Aflibercept 8
RxNorm normalized name: AFLIBERCEPT 8MG/0.07ML INJ,SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 8 mg every 12 weeks (8q12)
Trial: 38461843
Drug: Aflibercept 8
RxNorm normalized name: AFLIBERCEPT 8MG/0.07ML INJ,SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 8 mg every 16 weeks (8q16)
Trial: 38461843
Drug: Aflibercept 2
RxNorm normalized name: ziv-aflibercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 2 mg every 8 weeks (2q8)
Trial: 38461841
Drug: Aflibercept 8
RxNorm normalized name: AFLIBERCEPT 8MG/0.07ML INJ,SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 8 mg every 12 weeks (8q12) vs 2q8
Trial: 38461841
Drug: Aflibercept 8
RxNorm normalized name: AFLIBERCEPT 8MG/0.07ML INJ,SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 8 mg every 16 weeks (8q16) vs 2q8
Trial: 38462673
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg rifampicin daily (flat dose)
Trial: 38462751
Drug: Short regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short regimen containing high-dose moxifloxacin and clofazimine
Trial: 38462760
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as prevention (TasP)
Trial: 38462764
Drug: Eltrombopag, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag, daily fixed-dose for 6 months
Trial: 38463163
Drug: Mixed RV1-RV5
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed RV1-RV5 vaccine schedules
Trial: 38463541
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks) + External Beam Radiation Therapy (EBRT, median dose: 50 Gy)
Trial: 38509495
Drug: Therapeutic plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIG)
Trial: 38465515
Drug: Apraglutide 5
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apraglutide 5 mg administered subcutaneously
Trial: 38466266
Drug: Monthly intervention
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly intervention (9 monthly video lessons and 1 week of self-monitoring per month)
Trial: 38466266
Drug: Control intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control intervention (monthly online newsletters)
Trial: 38466274
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (n=1541)
Trial: 38466274
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (n=1459)
Trial: 38466972
Drug: Oral CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CBD therapy (2.5 mg per kg per day for 16 days)
Trial: 38467003
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and Vitamin D supplementation (1000 mg of calcium carbonate with 400 IU of vitamin D)
Trial: 38467131
Drug: Venetoclax monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax monotherapy (400 mg oral once daily after a 5-week ramp-up)
Trial: 38467383
Drug: Biofeedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback treatment (n=19)
Trial: 38467383
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n=23)
Trial: 38467604
Drug: Neoadjuvant chemoimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoimmunotherapy with camrelizumab (200 mg), nab-paclitaxel (260 mg/m2), and cisplatin (dosage not specified)
Trial: 38467716
Drug: Traditional Sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Sound Therapy (TST)
Trial: 38467945
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement (IIP) without grafting
Trial: 38467945
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement (IIP) with autogenous tooth bone graft (ATBG)
Trial: 38467945
Drug: Simvastatin (SMV)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin (SMV) gel mixed with ATBG around IIP
Trial: 38468231
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline VEGF receptor-2 level
Trial: 38468259
Drug: 2000 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg/day quercetin for 6 months
Trial: 38468293
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy (EXP)
Trial: 38468338
Drug: High-frequency plasma
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency plasma donors (HFPDs) donating 650 mL of plasma 3 times every 2 weeks
Trial: 38468338
Drug: Regular-frequency plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-frequency plasma donors (RFPDs) donating 650 mL of plasma 1 time every 2 weeks
Trial: 38468418
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy for insomnia (CBT-I)
Trial: 38469686
Drug: Immediate curative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate curative therapy (radiotherapy or prostatectomy)
Trial: 38469686
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy (endocrine therapy or observation)
Trial: 38470404
Drug: Chemotherapy (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (paclitaxel or doxorubicin)
Trial: 38470420
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg subcutaneously for 6 months
Trial: 38470420
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment of cardiovascular risk factors (control group) for 6 months
Trial: 38470460
Drug: Nthabi health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nthabi health promotion app used on smartphones or tablets for up to 6 weeks
Trial: 38471063
Drug: Third-party, single-donor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-party, single-donor fecal microbiota transplantation (FMT) administered in combination with systemic corticosteroids. Induction dose: 15 capsules per day for 2 consecutive days, followed by 3 weekly maintenance doses of 15 capsules each.
Trial: 38471416
Drug: Durvalumab in
RxNorm normalized name: durvalumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab in combination with cCRT
Trial: 38471508
Drug: i.p. nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.p. nivolumab monotherapy
Trial: 38471711
Drug: Cemiplimab 600
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 600 mg intravenously Q4W for up to 48 weeks
Trial: 38471711
Drug: Cemiplimab 600
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 600 mg intravenously Q4W
Trial: 38471825
Drug: Suspension of
RxNorm normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension of Rilonacept
Trial: 38471990
Drug: Mito-MES 20
RxNorm normalized name: Mito-4509
DrugBank: Mito-4509 (DB05846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mito-MES 20 mg daily for 14 days
Trial: 38472381
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of absorbent pyjama pants (APP) after a 4-week run-in period.
Trial: 38472696
Drug: Daridorexant 50
RxNorm normalized name: daridorexant 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daridorexant 50 mg (single and multiple doses)
Trial: 38472696
Drug: Daridorexant 50
RxNorm normalized name: daridorexant 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daridorexant 50 mg (single dose)
Trial: 38472696
Drug: Midazolam 2
RxNorm normalized name: midazolam 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2 mg and Warfarin 25 mg (concomitant administration)
Trial: 38473239
Drug: CC-96191, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-96191, a novel CD33/CD16a/NKG2D immune-modulating TriNKET
Trial: 38473248
Drug: Besifovir (BSV)
RxNorm normalized name: Besifovir
DrugBank: Besifovir (DB15671)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besifovir (BSV) treatment for up to 8 years
Trial: 38475764
Drug: Intra-articular gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular gold micro-particles with hyaluronic acid (20 mg, 72,000 particles, 20-40 μm in diameter)
Trial: 38475765
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of planned therapies
Trial: 38475765
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to systemic therapy
Trial: 38475765
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to subsequent treatment
Trial: 38475786
Drug: Anakinra (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (human interleukin 1 receptor antagonist)
Trial: 38475822
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (AT2) therapy
Trial: 38475822
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) vasopressor therapy
Trial: 38476466
Drug: Pimavanserin (34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin (34 mg, once daily)
Trial: 38476961
Drug: Dichoptic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichoptic therapy with eye-tracking, 1.5 hours, 6 days per week for 1 month
Trial: 38476961
Drug: Dichoptic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichoptic therapy with eye-tracking, continued for 4 months
Trial: 38477675
Drug: Low-Dose Morphine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Morphine
Trial: 38477988
Drug: RSVPreF3-Mat vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVPreF3-Mat vaccine
Trial: 38478042
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid (FA) dosages ranging from 0-1.6 mg combined with 10 mg enalapril maleate, taken daily for 8 weeks
Trial: 38478255
Drug: Outpatient parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient parenteral antimicrobial therapy (OPAT) with anti-infective medications administered at home using elastomeric pumps for a median duration of 15 days.
Trial: 38478366
Drug: Silymarin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (150 to 300 mg twice a day)